Literature DB >> 23452638

Treatment strategies for esophageal cancer.

Dylan R Nieman1, Jeffrey H Peters.   

Abstract

The treatment of esophageal cancer has evolved considerably in the past decade and depends largely on the extent of disease at the time of presentation. For disease confined to the esophageal mucosa, endoscopic therapy is replacing esophagectomy as the standard of care. For locoregional disease, neoadjuvant chemoradiation followed by esophagectomy is the best strategy for optimizing long-term survival. In the minority of patents who present with metastatic disease, the prognosis is poor. Palliative therapies available for these patients include chemotherapy, radiation, endoscopic therapies to ameliorate obstruction or bleeding, and surgical intervention to optimize nutritional status or to relieve obstruction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23452638     DOI: 10.1016/j.gtc.2012.11.007

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  9 in total

1.  Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.

Authors:  Drexell Hunter Boggs; Andrew Hanna; Whitney Burrows; Naomi Horiba; Mohan Suntharalingam
Journal:  J Gastrointest Cancer       Date:  2015-06

2.  Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma.

Authors:  Yu-Cheng Lee; Cheng-Han Lin; Wei-Lun Chang; Wen-Der Lin; Jhih-Kai Pan; Wei-Jan Wang; Bor-Chyuan Su; Hsien-Hui Chung; Chen-Hsun Tsai; Forn-Chia Lin; Wen-Ching Wang; Pei-Jung Lu
Journal:  Int J Mol Sci       Date:  2022-04-14       Impact factor: 6.208

3.  Clinical results of multimodality therapy for esophageal cancer with distant metastasis.

Authors:  Masakuni Sakaguchi; Toshiya Maebayashi; Takuya Aizawa; Naoya Ishibashi; Tsutomu Saito
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer.

Authors:  Yaqin Zhao; Lu Chen; Shu Zhang; Qiang Wu; Xiaoqin Jiang; Hong Zhu; Jin Wang; Zhiping Li; Yong Xu; Ying Jie Zhang; Sen Bai; Feng Xu
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

5.  Surgery Combined with Radiotherapy Improved Survival in Metastatic Esophageal Cancer in a Surveillance Epidemiology and End Results Population-based Study.

Authors:  San-Gang Wu; Wei-Hao Xie; Zhao-Qiang Zhang; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Zhen-Yu He
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

6.  Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study.

Authors:  Jiahua Lyu; Tao Li; Qifeng Wang; Fang Li; Peng Diao; Li Liu; Churong Li; Jinyi Lang
Journal:  Radiat Oncol       Date:  2018-11-26       Impact factor: 3.481

7.  Identification of prognostic miRNA biomarkers for esophageal cancer based on The Cancer Genome Atlas and Gene Expression Omnibus.

Authors:  Jinru Xue; Erna Jia; Na Ren; Hua Xin
Journal:  Medicine (Baltimore)       Date:  2021-02-19       Impact factor: 1.817

8.  Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.

Authors:  Falk Roeder; Nils H Nicolay; Tam Nguyen; Ladan Saleh-Ebrahimi; Vasilis Askoxylakis; Tilman Bostel; Felix Zwicker; Juergen Debus; Carmen Timke; Peter E Huber
Journal:  Radiat Oncol       Date:  2014-08-29       Impact factor: 3.481

9.  Mesenchymal Stromal Cells-Derived β2-Microglobulin Promotes Epithelial-Mesenchymal Transition of Esophageal Squamous Cell Carcinoma Cells.

Authors:  Junjie Wang; Weilin Yang; Tao Wang; Xiaoyong Chen; Jiancheng Wang; Xiaoran Zhang; Chuang Cai; Beilong Zhong; Jiabin Wu; Zhenguang Chen; Andy Peng Xiang; Weijun Huang
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.